In the BioHarmony Drug Report Database

"Preview" Icon

Netupitant

Akynzeo (netupitant) is a small molecule pharmaceutical. Netupitant was first approved as Akynzeo on 2014-10-10. It has been approved in Europe to treat nausea, neoplasms, and vomiting. It is known to target substance-P receptor. Akynzeo’s patents are valid until 2035-09-25 (FDA).

 

Trade Name

 

Akynzeo
 

Common Name

 

netupitant
 

ChEMBL ID

 

CHEMBL206253
 

Indication

 

nausea, neoplasms, vomiting
 

Drug Class

 

Tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists

Image (chem structure or protein)

Netupitant structure rendering